The Online Investor
Home
Dividends
25 Safe Dividends
Stock Splits
Mergers & Acquisitions
Business Services/Equipment M&A

Construction M&A
   General Contractors & Builders M&A
Consumer Goods M&A
   Sporting Goods & Activities M&A
   Office Supplies M&A
   Food & Beverage M&A
   Beverages & Wineries M&A
   Cigarettes & Tobacco M&A
   Marijuana Stocks M&A
   Apparel Stores M&A
   Department Stores M&A
   Grocery & Drug Stores M&A
   Electronics Stores M&A
   Home Improvement Stores M&A
   Home Furnishing Stores M&A
   Auto Dealerships M&A
   Specialty Retail M&A
Consumer Services M&A
   Education & Training Services M&A
Energy M&A
   Oil & Gas Refining & Marketing M&A
   Oil & Gas Exploration & Production M&A
   Oil & Gas Equipment & Services M&A
Financial M&A
   Banking & Savings M&A
   Investment Brokerages M&A
   Investment Companies & Venture Capital M&A
   Asset Management M&A
   Credit Services & Lending M&A
   Life & Health Insurance M&A
   Insurance Brokers M&A
Healthcare M&A
   Drugs & Pharmaceuticals M&A
   Biotechnology M&A
   Diagnostics M&A
   Medical Instruments & Supplies M&A
   Hospital & Medical Practitioners M&A
Industrial M&A
   Chemicals M&A
   Specialty Chemicals M&A
   Defense M&A
   Aerospace & Defense M&A
   Construction Materials & Machinery M&A
   Industrial Machinery & Equipment M&A
Manufacturing M&A
   Home Furnishings & Furniture M&A
   Auto Manufacturers M&A
   Auto Parts M&A
   Textiles & Apparel M&A
Materials M&A
   Agricultural Chemicals M&A
   Rubber & Plastics M&A
   Paper & Forest Products M&A
   Packaging & Containers M&A
   Agriculture & Farm Products M&A
Media M&A
   Advertising M&A
   Television & Radio M&A
   Publishing & Printing M&A
Metals & Mining M&A
   Precious Metals M&A
   Non-Precious Metals & Non-Metallic Mining M&A
   Metals Fabrication & Products M&A
Real Estate M&A
   REITs M&A
Technology M&A
   Electronic Equipment & Products M&A
   3D Printing Stocks M&A
   Computers M&A
   Computer Peripherals M&A
   Application Software M&A
   Semiconductors M&A
   Information Technology Services M&A
Transportation M&A
   Air Services Other M&A
   Airlines M&A
   Trucking M&A
   Shipping M&A
   Railroads M&A
Travel & Entertainment M&A
   Hotels, Lodging, Restaurants & Travel M&A
   Entertainment M&A
Utilities M&A
   Waste Management M&A
   Communications Services M&A
   Electric Utilities M&A
   Gas Utilities M&A
   Water Utilities M&A
Mega Mergers
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Stock Buybacks
IPOs
Secondary Offerings
Top 20 Large Caps
Top 20 Biggest ETFs
Insider Buying
Top 25 Low PE Ratios
Analyst Actions
25 Top Analyst Picks
Articles
CAGR Calculator
Dunnan On Dollars
10 Pot Stocks
ETF Center
Knowledge Center
Retirement Center
Advertising Opportunities
Privacy Policy
Disclaimer Statement

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Tue., Apr. 16, 3:32 AM

This Slide: #78 of 100

Slide #78. ARCA biopharma, Inc. — Oruka Therapeutics

Acquirer: ARCA biopharma, Inc. (NASDAQ:ABIO)
Acquiree: Oruka Therapeutics
Details: ARCA biopharma, Inc. (NASDAQ: ABIO) ("ARCA"), and Oruka Therapeutics ("Oruka"), a privately held biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, announced today that they have entered into a definitive agreement to combine the companies in an all-stock transaction. The resulting entity will focus on advancing Oruka's pipeline of potentially best-in-class biologics, including ORKA-001 (an IL-23p19 inhibitor) and ORKA-002 (an IL-17A/F inhibitor). Upon completion of the merger, the combined company plans to operate under the name Oruka Therapeutics, Inc. and trade on Nasdaq under the ticker symbol "ORKA".

ARCA biopharma is a clinical-stage biopharmaceutical company. Co.'s primary product candidates are Recombinant Nematode Anticoagulant Protein c2 (rNAPc2 (AB201)) as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro™ (bucindolol hydrochloride) for the treatment of atrial fibrillation in patients with chronic heart failure. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Open the ABIO Page at The Online Investor »

ABIO — Key Stats (updated 17 hours, 4 minutes ago)
Company Name:  ARCA biopharma Inc
Website:  www.arcabiopharma.com
Sector:  Biotechnology
Number of ETFs Holding ABIO:  2
Total Market Value Held by ETFs:  $1.45M
Total Market Capitalization:  $47.00M
% of Market Cap. Held by ETFs:  3.09%
 

Open the ABIO Page at The Online Investor (in a new window) »
April 16, 2024  •  3:32 AM Eastern
ABIO — Current Quote
Quotes delayed 20 minutes

Email EnvelopeFree ABIO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts
Avg. Broker Rec.

Buy (3.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.